What's happening in the industry

Institute of Pathology joins Thermo Fisher Scientific to drive oncology companion diagnostic development read on...

Seeking an edge in a fiercely fought field, Bristol-Myers pays Halozyme $105M to access I-O delivery tech read on...

Cancer immunotherapy proves itself in earlier-stage disease read on...

Nivolumab now available for lung cancer after company offers NICE new CDF deal read on...

Foundation Medicine blood test for tumor mutational burden to be used by Roche as companion diagnostic test in late-stage lung cancer study read on...

Konica Minolta accelerates expansion of precision medicine business through acquisition of US-based pharmaceutical research company, Invicro read on...

BioMarker Strategies announces Phase II National Cancer Institute grant to continue development of companion diagnostic test to help select optimal therapy for patients with non-small cell lung cancer read on...

BERG broadens relationship with the Department of Defense (DoD) Center for Prostate Disease Research with new predictive biomarker test for prostate cancer read on...

Interim results from Biodesix® study indicate that VeriStrat testing impacts treatment decisions across all stages of non-small cell lung cancer read on...

Treos Bio enters into agreement with PPD to manage first-in-man trial of its lead therapeutic cancer vaccine program read on...

Swedish Cancer Institute, GNS Healthcare launch precision medicine collaboration read on...

Tempus and Cleveland Clinic collaborate on personalized medicine initiative read on...

Biopharma intelligence firm Ozmosi aims to include almost all clinical trials around the world on a single platform read on...

Mustang picks up CD20 CAR-T from Fred Hutch read on...

Discussing cancer costs can reduce treatment expenses read on...

GSK bets on pioneering cancer therapy with Adaptimmune deal read on...

AstraZeneca rebuilds cancer drug hopes with new lung data read on...

Pfizer and Astellas announce positive results from Phase 3 Prosper trial of Xtandi in prostate cancer read on...

Tesaro's ovarian cancer drug gets EU agency backing read on...

Novartis drug Rydapt receives EU approval for newly diagnosed FLT3-mutated AML and three types of advanced systemic mastocytosis read on...

China's drugmakers boast big pharma option value read on...

FDA approves Mylotarg for treatment of acute myeloid leukemia read on...

NCCN guidelines to include categories of preference read on...

Kite-Gilead: Winners and losers Part 2 read on...

Rosetta Genomics enters into agreement to sell its PersonalizeDx business to Pragmin Prognosis read on...

FDA approves Novartis treatment that alters patients’ cells to fight cancer read on...

MDUFA IV: Most US FDA user fees for medical device companies jump 33% or more in 2018 read on...

What you might have missed

Download our latest Ebook - PD-L1: The Story So Far
Expert Insight - Liquid biopsy: clearing the barriers to support pharma, labs and patients
Article from G2 Intelligence - Companion diagnostics driving new model for pharma-Dx partnerships